Genetic Test Identifies Patients at Highest Risk for Prostate Cancer Recurrence

Share this content:

the Cancer Therapy Advisor take:

According to new findings published in the journal Lancet Oncology, researchers at Princess Margaret Cancer Centre and the Ontario Institute for Cancer Research in Toronto, Ontario, Canada, have designed a genetic test that can determine which men are at the highest risk for developing prostate cancer recurrence following localized surgery or radiotherapy.

The test works by analyzing pre-treatment biopsy tissue to identify abnormal DNA of the cancer and its oxygen content. It is well known that hypoxia promotes the spread of prostate cancer. Using both factors, the test can determine in 3 days with nearly 80% accuracy which patients with prostate cancer have the highest risk for disease recurrence. The researchers studied the test in two groups of patients.

The first group of men were treated with image-guided radiotherapy and were followed for 7.8 years, on average. The second group underwent radical prostatectomies. Results were similar in both groups. They found that men who had low levels of genetic alterations and low hypoxia had less than a 7% recurrence rate at 5 years.

Men with high levels of genetic mutations and high hypoxia had greater than a 50% recurrence rate at 5 years. The test will help determine who will need chemotherapy or hormone therapy in addition to radiotherapy or surgery.

The time is right for new guidelines on metastatic castration-resistant prostate cancer.
New genetic test can determine which men are at the highest risk for developing prostate cancer recurrence.
Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. 
READ FULL ARTICLE From News Medical

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs